Business Context and Reporting Period
Zentalis Pharmaceuticals, Inc. (ZNTL) is a clinical-stage biopharmaceutical company focused on developing azenosertib (ZN-c3), a WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). This Form 10-Q covers the quarterly and nine-month periods ended September 30, 2025. The company operates as a single segment and is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $40,560 |
| Net Loss | $(26,691) | $(40,158) | $(101,844) | $(118,367) |
| Net Loss Per Share (Basic/Diluted) | $(0.37) | $(0.56) | $(1.42) | $(1.67) |
| Operating Expenses | $33,734 | $51,432 | $115,415 | $181,905 |
| Cash & Cash Equivalents | $39,072 | $41,320 | $39,072 | $41,320 |
| Marketable Securities | $239,219 | $318,009 | $239,219 | $318,009 |
| Total Liquidity (Cash + Securities) | $278,291 | $359,329 | $278,291 | $359,329 |
| Accumulated Deficit | $(1,156,239) | $(1,006,923) | $(1,156,239) | $(1,006,923) |
Note: Revenue in 9M 2024 consisted of license revenue from the Immunome agreement. No product revenue has been generated to date.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 34% in Q3 2025 compared to Q3 2024 ($33.7M vs. $51.4M) and by 36% for the nine-month period ($115.4M vs. $181.9M). This reduction is primarily attributed to a strategic restructuring in January 2025 that reduced the workforce by approximately 40%.
- Restructuring Costs: The company incurred $7.8 million in restructuring charges during the nine months ended September 30, 2025, compared to zero in the prior year period. These costs were largely incurred in Q1 2025.
- Revenue Absence: License revenue was $0 for the nine months ended September 30, 2025, compared to $40.6 million in the same period in 2024. The 2024 revenue related to the Immunome license agreement, which has since been terminated and converted to an asset sale.
- Investment Income: Investment and other income decreased to $7.0 million in Q3 2025 from $11.2 million in Q3 2024, driven by lower returns on invested cash and changes in the fair value of Immunome common stock.
- Asset Impairment: A $1.2 million impairment charge was recorded in Q1 2025 related to research and development equipment.
Guidance, Outlook, and Risks
- Clinical Outlook: The company is advancing the DENALI Part 2 clinical trial of azenosertib in Cyclin E1-positive PROC. The first patient was dosed in Part 2a in April 2025. Topline data from DENALI Part 2 is anticipated by year-end 2026. A Phase 3 confirmatory study is planned to be conducted concurrently with DENALI Part 2b.
- Liquidity Runway: Management believes existing cash, cash equivalents, and marketable securities ($280.7 million as of September 30, 2025) are sufficient to fund operations into late 2027.
- Government Shutdown Risk: The filing notes a U.S. government shutdown beginning October 1, 2025, which may impact the FDA's ability to review regulatory submissions and the company's access to capital markets.
- Capital Needs: The company expects to continue incurring significant net losses and will require substantial additional capital to complete development and commercialization. It has an "At-The-Market" (ATM) program with $75.0 million remaining available for sale.
- Key Risks: Dependence on the success of azenosertib; potential delays in clinical trials or regulatory approval; need for a companion diagnostic for Cyclin E1-positive patients; and the impact of macroeconomic conditions on capital raising.
Investor Verification Checklist
- Cash Runway Validation: Verify the accuracy of the "late 2027" liquidity projection given the recent government shutdown and potential for increased capital requirements for the Phase 3 trial.
- Restructuring Completion: Confirm that all restructuring charges ($7.8M) have been fully paid or accrued and that the anticipated cost savings are being realized in subsequent quarters.
- Immunome Asset Sale: Review the status of the remaining Immunome common stock holdings (0.2 million shares held as of Sept 30, 2025, sold in Oct 2025) and the realization of the $5.0 million contingent milestone payment.
- Companion Diagnostic: Assess the progress of the diagnostic partner in developing the Cyclin E1 companion diagnostic, as regulatory approval for azenosertib is contingent upon this.
- Share-Based Compensation: Monitor the trend in share-based compensation expense, which decreased significantly year-over-year ($17.6M for 9M 2025 vs. $35.9M for 9M 2024) due to the workforce reduction.